Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The 5-HT 2C receptor agonist lorcaserin reduces cocaine self-administration, reinstatement of cocaine-seeking and cocaine induced locomotor activity
Colin Harvey-Lewis, Zhaoxia Li, Guy A. Higgins, et al.
Neuropharmacology (2015) Vol. 101, pp. 237-245
Closed Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function
Nicholas M. Barnes, Gerard P. Ahern, Carine Bécamel, et al.
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 310-520
Open Access | Times Cited: 204
Improving translation of animal models of addiction and relapse by reverse translation
Marco Vènniro, Matthew L. Banks, Markus Heilig, et al.
Nature reviews. Neuroscience (2020) Vol. 21, Iss. 11, pp. 625-643
Closed Access | Times Cited: 179
Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats
Harshini Neelakantan, Erica Holliday, Robert G. Fox, et al.
ACS Chemical Neuroscience (2017) Vol. 8, Iss. 5, pp. 1065-1073
Open Access | Times Cited: 90
A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment
J.M. Palacios, Ángel Pazos, Daniël Hoyer
Psychopharmacology (2017) Vol. 234, Iss. 9-10, pp. 1395-1418
Open Access | Times Cited: 83
Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential
Guy A. Higgins, Paul Fletcher, William Shanahan
Pharmacology & Therapeutics (2019) Vol. 205, pp. 107417-107417
Closed Access | Times Cited: 67
The serotonin 5-HT2Creceptor and the non-addictive nature of classic hallucinogens
Clinton E. Canal, Kevin S. Murnane
Journal of Psychopharmacology (2016) Vol. 31, Iss. 1, pp. 127-143
Open Access | Times Cited: 54
Activation of Ventral Tegmental Area 5-HT2C Receptors Reduces Incentive Motivation
Lourdes Valencia-Torres, Cristian M. Olarte‐Sánchez, D. Lyons, et al.
Neuropsychopharmacology (2016) Vol. 42, Iss. 7, pp. 1511-1521
Open Access | Times Cited: 53
Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development
Eric A. Wold, Christopher Wild, Kathryn A. Cunningham, et al.
Current Topics in Medicinal Chemistry (2019) Vol. 19, Iss. 16, pp. 1381-1398
Open Access | Times Cited: 46
Effects of Lorcaserin on Cocaine and Methamphetamine Self-Administration and Reinstatement of Responding Previously Maintained by Cocaine in Rhesus Monkeys
Lisa R. Gerak, Gregory T. Collins, Charles P. France
Journal of Pharmacology and Experimental Therapeutics (2016) Vol. 359, Iss. 3, pp. 383-391
Open Access | Times Cited: 44
Incubation of cocaine cue reactivity associates with neuroadaptations in the cortical serotonin (5-HT) 5-HT2C receptor (5-HT2CR) system
Sarah E. Swinford-Jackson, Noelle C. Anastasio, Robert G. Fox, et al.
Neuroscience (2016) Vol. 324, pp. 50-61
Open Access | Times Cited: 41
Repeated 7-Day Treatment with the 5-HT2C Agonist Lorcaserin or the 5-HT2A Antagonist Pimavanserin Alone or in Combination Fails to Reduce Cocaine vs Food Choice in Male Rhesus Monkeys
Matthew L. Banks, S. Stevens Negus
Neuropsychopharmacology (2016) Vol. 42, Iss. 5, pp. 1082-1092
Open Access | Times Cited: 39
The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study
Jimmie L. Pirtle, Melissa D. Hickman, Varun C. Boinpelly, et al.
Pharmacology Biochemistry and Behavior (2019) Vol. 180, pp. 52-59
Open Access | Times Cited: 39
Molecular and behavioral responses of zebrafish embryos/larvae after sertraline exposure
Huiting Yang, Xuefang Liang, Yanyan Zhao, et al.
Ecotoxicology and Environmental Safety (2020) Vol. 208, pp. 111700-111700
Open Access | Times Cited: 34
Enhancing translation: A need to leverage complex preclinical models of addictive drugs to accelerate substance use treatment options
Christa Corley, Ashley Craig, Safiyah Sadek, et al.
Pharmacology Biochemistry and Behavior (2024) Vol. 243, pp. 173836-173836
Open Access | Times Cited: 4
The central serotonin2B receptor as a new pharmacological target for the treatment of dopamine-related neuropsychiatric disorders: Rationale and current status of research
Céline Devroye, Adeline Cathala, Pier Vincenzo Piazza, et al.
Pharmacology & Therapeutics (2017) Vol. 181, pp. 143-155
Closed Access | Times Cited: 37
The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders
Gregory T. Collins, Lisa R. Gerak, Charles P. France
Neuropharmacology (2017) Vol. 142, pp. 63-71
Open Access | Times Cited: 36
Choice between delayed food and immediate opioids in rats: treatment effects and individual differences
Leigh V. Panlilio, Maria E. Secci, Charles W. Schindler, et al.
Psychopharmacology (2017) Vol. 234, Iss. 22, pp. 3361-3373
Open Access | Times Cited: 35
Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder
Laura Brandt, Jermaine D. Jones, Suky Martinez, et al.
Drug and Alcohol Dependence (2020) Vol. 208, pp. 107859-107859
Open Access | Times Cited: 29
Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia
Tom H. Johnston, Alix M.B. Lacoste, Paula Ravenscroft, et al.
Neuropharmacology (2024) Vol. 248, pp. 109880-109880
Open Access | Times Cited: 3
Lorcaserin decreases the reinforcing effects of heroin, but not food, in rhesus monkeys
Stephen J. Kohut, Jack Bergman
European Journal of Pharmacology (2018) Vol. 840, pp. 28-32
Open Access | Times Cited: 31
Role of impulsivity and reward in the anti-obesity actions of 5-HT2Creceptor agonists
Guy A. Higgins, Fiona D. Zeeb, Paul Fletcher
Journal of Psychopharmacology (2017) Vol. 31, Iss. 11, pp. 1403-1418
Closed Access | Times Cited: 30
The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites
Elena K. Schneider‐Futschik, Rachel M. McQuade, Vincenzo Carbone, et al.
ERJ Open Research (2018) Vol. 4, Iss. 1, pp. 00127-2017
Open Access | Times Cited: 30
Effects of lorcaserin on reinstatement of responding previously maintained by cocaine or remifentanil in rhesus monkeys.
Lisa R. Gerak, Gregory T. Collins, David R. Maguire, et al.
Experimental and Clinical Psychopharmacology (2018) Vol. 27, Iss. 1, pp. 78-86
Open Access | Times Cited: 28
Lorcaserin bidirectionally regulates dopaminergic function site-dependently and disrupts dopamine brain area correlations in rats
Philippe De Deurwaerdère, Marta Ramos, Rahul Bharatiya, et al.
Neuropharmacology (2019) Vol. 166, pp. 107915-107915
Closed Access | Times Cited: 27
Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration
Noelle C. Anastasio, Dennis J. Sholler, Robert G. Fox, et al.
Neuropharmacology (2020) Vol. 168, pp. 108009-108009
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top